CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1

The Journal of Urology
A SatheR Nawroth

Abstract

The retinoblastoma signaling network is frequently altered in advanced bladder cancer. We investigated the potential of CDK4/6 as a therapeutic target and determined biomarkers for patient stratification. Genetic alterations were analyzed using public databases, including TCGA (The Cancer Genome Atlas), COSMIC (Catalogue of Somatic Mutations in Cancer) and CCLE (Cancer Cell Line Encyclopedia). Effects of the CDK4/6-inhibitor PD-0332991 or LY2835219 were examined in 10 bladder cancer cell lines by immunoblot, cell viability, apoptosis and cell cycle progression. Efficacy of the PD-0332991 and cisplatin combination was analyzed using the combination index. Gene expression level was determined by quantitative polymerase chain reaction. Cytomegalovirus promoter regulated recombinant retinoblastoma was used for reconstitution. Three-dimensional xenografts were grown on chicken chorioallantoic membrane and analyzed by measuring tumor weight and immunohistochemical expression of total retinoblastoma and Ki-67. PD-0332991 treatment decreased the proliferation of retinoblastoma positive bladder cancer cell lines and was synergistic in combination with cisplatin. PD-0332991 or LY2835219 treatment decreased the phosphorylation, total prot...Continue Reading

References

Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Jul 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans von der MaaseMichael Arning
Jun 13, 2008·Nature Protocols·Thomas D Schmittgen, Kenneth J Livak
Feb 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Erik S Knudsen, Jean Y J Wang
Jun 11, 2010·Proceedings of the National Academy of Sciences of the United States of America·W Ruprecht WiedemeyerLynda Chin
Oct 19, 2010·Nucleic Acids Research·Simon A ForbesP Andrew Futreal
Feb 1, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gottfried E KonecnyDennis J Slamon
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Aug 30, 2011·Biochemical and Biophysical Research Communications·Yoshiki KatsumiHajime Hosoi
Feb 4, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·James A KrausRohit Bhargava
Apr 4, 2013·Science Signaling·Jianjiong GaoNikolaus Schultz
Jan 31, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jan 31, 2015·Nature Reviews. Drug Discovery·Uzma AsgharErik S Knudsen
Mar 21, 2015·Drugs·Sohita Dhillon

❮ Previous
Next ❯

Citations

Feb 13, 2020·International Journal of Molecular Sciences·Sruthi V HindupurRoman Nawroth
Jul 25, 2019·Journal of Experimental & Clinical Cancer Research : CR·Zhichao TongRoman Nawroth
Jun 9, 2020·Cancer Immunology, Immunotherapy : CII·Qilai LongChong-Xian Pan
Apr 26, 2017·Journal of Hematology & Oncology·Hanxiao XuKongming Wu
Aug 7, 2019·Molecular Cancer Research : MCR·Teena DhirJonathan R Brody
May 1, 2021·Journal of Personalized Medicine·Florian G KleinRoman Nawroth

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Acta geneticae medicae et gemellologiae
F FaraldiG Alfieri
Progress in Cell Cycle Research
M Hatakeyama, R A Weinberg
New Jersey Medicine : the Journal of the Medical Society of New Jersey
T Shimamura, S Takahashi
© 2021 Meta ULC. All rights reserved